Pharmaceuticals

Beovu Lawsuits

Beovu LawsuitsThe U.S. Food and Drug Administration (FDA) has approved a new warning label for the prescription drug Beovu (brolucizumab). The update includes additional precautions concerning retinal vasculitis and retinal vascular occlusion for patients taking Beovu, which is prescribed for the treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD). The new warning was announced by Novartis after it concluded that adverse ophthalmological conditions occurred in patients taking Beovu.
 

Beovu Lawyers are Ready to Help

Contact our Beovu Lawyers to review whether you or a family member may be entitled to financial compensation. Levy Konigsberg LLP is currently accepting Beovu cases in all 50 states.

If you or a loved one has suffered one or more of these complications, you may be entitled to a cash award and compensation for medical expenses. For a free confidential consultation with Beovu Lawyers at our law firm, please call 1-800-988-8005 or submit an email inquiry above.
 

What is Beovu?

Beovu is an intravitreal injection used to treat wet age-related macular degeneration (AMD). Wet AMD occurs when abnormal blood vessels grow beneath the retina and macula. When the blood vessels leak, the macula can swell and alter one’s vision. Patients with this condition may see dark spots in their central vision. This can lead to severe and instant vision loss. The “wet” type of macular degeneration accounts for about 10-15% of all cases of macular degeneration.
 

What is Happening with Beovu?

A new label approved by the FDA warns patients taking Beovu of the risks of retinal vasculitis and retinal vascular occlusion. Novartis, the manufacturer of Beovu, received reports of vasculitis in fourteen patients being treated with the medication since it received FDA approval in October 2019. In February 2020, the American Society of Retina Specialists (ASRS) expressed concerns about vasculitis (inflammation of the blood vessels) in these fourteen patients. Retinal vasculitis, a serious condition that can lead to blindness, was reported in eleven of these cases.

Novartis conducted an internal review and initiated an external safety review committee to analyze these adverse conditions in patients. The committee verified a safety issue related to rare adverse events known as “retinal vasculitis” and “retinal vascular occlusion.” In addition to the change in U.S. labels, Novartis announced that it would pursue updates on labels worldwide in light of its findings.

https://www.reviewofophthalmology.com/article/beovu-labeling-to-be-updated-due-to-side-effects

https://www.medscape.com/viewarticle/932389
 

Beovu Common Side Effects and Complications

  • Reduced visual clarity;
  • Cataracts;
  • Broken blood vessels;
  • Floaters; and
  • Eye pain.

 
Serious complications of Beovu that may lead to complete vision loss include:

  • Retinal vasculitis (inflammation of the vascular branches of the retinal artery);
  • Retinal artery occlusion (blockage of the retinal artery carrying oxygen to the retina); and
  • Intraocular inflammation.

 

Beovu Lawyers are Ready to Help

Contact our Beovu Lawyers to review whether you or a family member may be entitled to financial compensation. Levy Konigsberg LLP is currently accepting Beovu cases in all 50 states.

If you or a loved one has suffered one or more of these complications, you may be entitled to a cash award and compensation for medical expenses. For a free confidential consultation with Beovu Lawyers at our law firm, please call 1-800-988-8005 or submit an email inquiry above.

For more information about the law firm's practice areas please contact Levy Konigsberg LLP at 1-212-605-6200 or 1-800-988-8005, 24 hours a day, 7 days a week.

Do You Have a Case?
Find Out Now.

National Offices

New York

800 Third Avenue, 11th Floor
New York, New York 10022
Telephone: 212-605-6200

New Jersey

101 Grovers Mill Rd, Ste 105
Lawrence Twp, NJ 08648
Telephone: 609-720-0400

Serving Clients Nationwide


Telephone: 800.988.8005

Attorney Advertising: Prior results do not guarantee a similar future outcome.